Structural Heart

This structural heart channel includes news, videos, podcasts and other content related to diagnosis and treatment of structural heart disease. Topics covered include heart valve repair and replacement, transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), left atrial appendage (LAA) occlusion, heart failure interventional device therapies, and closing holes in the heart using, including occlusion of atrial septal defects (ASDs), ventricular septal defects (VSDs) and patent foramen ovales (PFOs).

TCT 2020 Late-breaking Study trial Presentations Announced
Feature | TCT | September 17, 2020
September 17, 2020 — The late-breaking studies are one of the hallmarks of the annual Transcatheter Cardiovascular...
Videos | Structural Heart | September 16, 2020
Juan F. Granada, M.D., CEO of the Cardiovascular Research Foundation (CRF) explains structural heart innovations and...
Medtronic announced U.S. Food and Drug Administration (FDA) approval of an early feasibility study (EFS) of the Intrepid Transcatheter Tricuspid Valve Replacement (TTVR) system. The study begins on the heels of a recent Breakthrough Device Designation issued by the FDA for the Intrepid TTVR System. The Intrepid TTVR system is an investigational device worldwide.
News | Heart Valve Technology | September 11, 2020
September 11, 2020 – Medtronic announced U.S. Food and Drug Administration (FDA) approval of an early feasibility study...
An example of a 80-year-old TAVR patient planning CT scan from Northwestern Medicine's Central DuPage Hospital. This was used in a heart team meeting with the TAVR staff, including a cardiac surgeon and interventional cardiologist, to determine if this patient was eligable for TAVR, the best access routes to deliver the valve, device valve size needed, and to look for any potential anatomical issues so they can be planned for. 

An example of a 80-year-old TAVR patient planning CT scan from Northwestern Medicine's Central DuPage Hospital. This was used in a heart team meeting with the TAVR staff, including a cardiac surgeon and interventional cardiologist, to determine if this patient was eligible for TAVR, the best access routes to deliver the valve, device valve size needed, and to look for any potential anatomical issues so they can be planned for.

News | Structural Heart | September 02, 2020
September 2, 2020 — Northwestern Medicine Bluhm Cardiovascular Institute physicians recently completed their 2,000th...
Researchers 3-D Print Lifelike Heart Valve Models with embedded sensor technology
News | Medical 3-D Printing | September 02, 2020
September 2, 2020 — Patient-specific organ models are being used by the University of Minnesota to better prepare for...
Navin Kapur, M.D., FAHA, FACC, FSCAI, executive director, The CardioVascular Center for Research and Innovation (CVCRI), explains the concpet of the Door-to-Unloading (DTU) Trial he is heading, one of several innovations at Tufts Medical Center in Boston. Kapur is also director, Acute Mechanical Circulatory Support Program; director, interventional research laboratories; director of Cardiac Biology Research Center, Molecular Cardiology Research Institute (MCRI), Tufts Medical Center. Photo by Dave Fornell

Navin Kapur, M.D., FAHA, FACC, FSCAI, executive director, The CardioVascular Center for Research and Innovation (CVCRI), explains the concpet of the Door-to-Unloading (DTU) Trial he is heading, one of several innovations at Tufts Medical Center in Boston. Kapur is also director, Acute Mechanical Circulatory Support Program; director, interventional research laboratories; director of Cardiac Biology Research Center, Molecular Cardiology Research Institute (MCRI), Tufts Medical Center. Photo by Dave Fornell

Feature | Tufts Medical Center | August 21, 2020 | Dave Fornell, Editor
The cardiology program at Tufts Medical Center in Boston is internationally recognized for being on the forefront of...
Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization.

Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization. Read more on this FDA approval.

News | Left Atrial Appendage (LAA) Occluders | August 21, 2020
August 21, 2020 — According to a report published by Research Dive, the rising number of patients suffering from atrial...
National Survey Of Heart Valve Patients Shows Importance Of Seeking Treatment Early
News | Heart Valve Technology | August 12, 2020
August 12, 2020 — A national survey conducted by the patient advocacy group Heart-Valve-Surgery.com with support by...
The Conformal Medical CLAAS device, a next-generation transcatheter left atrial appendage (LAA) closure occluder for patients with atrial fibrillation (AF). LAA occlusion allows AFib patients to go off of life-long anticoagulation therapy. #LAA #LAAC

The Conformal Medical CLAAS device, a next-generation transcatheter left atrial appendage (LAA) closure occluder for patients with atrial fibrillation (AF). LAA occlusion allows AFib patients to go off of life-long anticoagulation therapy.

News | Left Atrial Appendage (LAA) Occluders | August 06, 2020
August 6, 2020 – Conformal Medical Inc. announced it secured $85 million in Series C financing to support the company’s...
CardioMech's transcatheter chordae tendineae repair system uses a catheter to attach an anchor on the mitral valve leaflet and then attaches it via a cord to the apex of the heart.

CardioMech's transcatheter chordae tendineae repair system uses a catheter to attach an anchor on the mitral valve leaflet and then attaches it via a cord to the apex of the heart.

News | Heart Valve Technology | August 05, 2020
August 5, 2020 – Minneapolis-based CardioMech AS, a medical device company developing a transfemoral, transseptally...
Two of the top pieces of content in July included the FDA clearance for the new Watchman FLX left atrial appendage occluder (left), which includes a video interview with one of the trial investigators. COVID-19 content remained among the top content in July, and one story explained the odd pattern of cardiac cell death in COVID-19 patient autopsies. 

Two of the top pieces of content in July included the FDA clearance for the new Watchman FLX left atrial appendage occluder (left), which includes a video interview with one of the trial investigators. COVID-19 content remained among the top content in July, and one story explained the odd pattern of cardiac cell death in COVID-19 patient autopsies.

Feature | August 03, 2020 | Dave Fornell, Editor
August 3, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC)...
A cardiac CT of a patient with pacemaker leads, which can be challenging to get good images due to metal artifact. This image was rendered from using Canon's AiCE AI-assisted interactive reconstruction with Global Illumination 3-D rendering from a scan on an Aquilion One Genesis SP system.

A cardiac CT of a patient with pacemaker leads, which can be challenging to get good images due to metal artifact. This image was rendered from using Canon's AiCE AI-assisted interactive reconstruction with Global Illumination 3-D rendering from a scan on an Aquilion One Genesis SP system.

Feature | CT Angiography (CTA) | July 27, 2020 | Dave Fornell, Editor
There has been tremendous growth in the field of cardiovascular computed tomography (CT) in the past two decades, with...
Videos | Left Atrial Appendage (LAA) Occluders | July 24, 2020
Devi G. Nair, M.D., FHRS, director of cardiac electrophysiology, St. Bernards Heart and Vascular Center, Jonesboro, Ark...
The U.S. Food and Drug Administration (FDA) has approved Boston Scientific's next generation Watchman FLX Left Atrial Appendage Closure (LAAC) Device.
News | Left Atrial Appendage (LAA) Occluders | July 22, 2020
July 22, 2020 — The U.S. Food and Drug Administration (FDA) has approved Boston Scientific's next generation Watchman...
The Edwards Konect Resilia aortic valved conduit (AVC).
News | Heart Valve Technology | July 15, 2020
July 15, 2020 —  The U.S. Food and Drug Administration (FDA) granted clearance for the Edwards Lifesciences Corp....